Sublingual immunotherapy with standardized quality grass allergen tablets: Results of the development program;Lyophylisierte graspollentablette zur sublingualen immuntherapie bei graspollenallergie: Aktueller wissensstand und ergebnisse des entwicklungsprogramms eines neuen präparats

Allergologie

Volumn 31, Issue 1, 2008, Pages 23-35

  Mohrenschlager M ^a   Kapp, A ^b   Kleine Tebbe, J ^c   Bachert, C ^d   Ring, J ^a   Wustenberg E G ^e  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c Allergie und Asthma Zentrum Westend   (Germany)

^d UZ Gent   (Belgium)

^e ALK SCHERAX Arzneimittel GmbH   (Germany)

Author keywords

Allergic rhinoconjunctivitis; Allergy vaccination; Clinical; Efficacy; Grass pollen; Oral lyophylisate; Safety; Specific immunotherapy; Studies; Sublingual application

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; BETA 2 ADRENERGIC RECEPTOR; BUDESONIDE; CORTICOSTEROID; DESLORATADINE; GRASS POLLEN ALLERGEN; GRAZAX; IMMUNOGLOBULIN G4; PLACEBO; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG QUALITY; DRUG SAFETY; FREEZE DRYING; HEALTH PROGRAM; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINOCONJUNCTIVITIS; SEROLOGY; UNSPECIFIED SIDE EFFECT;

EID: 38949162961     PISSN: 03445062     EISSN: None     Source Type: Journal    
DOI: 10.5414/alp31023     Document Type: Review

References (24)

1. Bachert C., U. Vestenbaek, J. Christensen, U.K. Griffiths, P.B. Poulsen: Cost-effectiveness of grass allergen tablet (Grazax) for the prevention of seasonal grass pollen-induced rhinoconjunctivitis - a Northern European perspective. Clin. Exp. Allergy. 37, 772-779 (2007).
2. Bousquet J. et al.: WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 53, 1-42 (1998).
3. Calderon M., M. Essendrop: Specific immunotherapy with high-dose SQ standardized grass allergen tablets was safe and well-tolerated. J. Invest. Allergol. Clin. Immunol. 16, 338-344 (2006).
4. Calderon M.A., B. Alves, M. Jacobson, B. Hurwitz, A. Sheikh, S. Durham: Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst. Rev. CD001936 (2007).
5. Calderon M.A., A.O. Birk, J.S. Andersen, S.R. Durham: Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy. Allergy 62, 958-961 (2007).
6. Cox L.S., D.L. Linnemann, H. Nolte, D. Weldon, I. Finegold, H.S. Nelson: Sublingual immunotherapy: a comprehensive review. J. Allergy Clin. Immunol. 117, 1021-1035 (2006).
7. Dahl R., A. Kapp, G. Colombo, J.G.R. de Monchy, S. Rak, W. Emminger, M. Fernandez Rivas, M. Ribel, S.R. Durham: Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 118, 434-440 (2006).
8. Dahl R., A. Stender, S. Rak: Specific immunotherapy with SQ-standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 6, 185-190 (2006).
9. Durham S.R., B. Riis: Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage. Allergy 62, 954-957 (2007).
10. Durham S.R., W.H. Yang, M.R. Pedersen, M. Johansen, S. Rak: Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 117, 802-809 (2006).
11. Emminger W., R. Dahl, A. Kapp, G. Colombo, J.G.R. de Monchy, S. Rak, B. Riis, S.R. Durham: Progressive effect of grass tablet immunotherapy during long-term treatment in patients with rhinoconjunctivitis. Allergy 62 (Suppl. 83), 240 (2007).
12. Frew A.J., R.J. Powell, C.J. Corrigan, S.R. Durham, UK Immunotherapy Study Group: Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 117, 319-325 (2006).
13. Ibañez M.D., F. Kaiser, R. Knecht, A. Armentia, H. Schöpfer, B. Tholstrup, A. Bufe: Safety of specific sublingual immunotherapy with SQ standardised grass allergen tables in children. Pediatr. Allergy Immunol. 18, 516-522 (2007).
14. Jacobsen L., B. Niggemann, S. Dreborg, H.A. Ferdousi, S. Halken, A. Høst, A. Koivikko, L.A. Norberg, E. Valovirta, U. Wahn, C. Möller, The PAT investigator group: Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 62, 943-948 (2007).
15. Kapp A., S. Rak, J.G.R. de Monchy, W. Emminger, G. Colombo, R. Dahl, P.M. Grønager, H. Henmar, S.R. Durham: Sublingual grass tablet immunotherapy shows a progressive immunological effect. Allergy 62 (Suppl. 83), 238 (2007).
16. Kleine-Tebbe J. et al.: Aktueller Stellenwert der sublingualen Immuntherapie bei allergischen Krankheiten. Allergo J. 13, 430-434 (2004).
17. Kleine-Tebbe J. et al.: Die spezifische Immuntherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen. Allergo J. 15, 56-74 (2006).
18. Kleine-Tebbe J., M. Ribel, D.A. Herold: Safety of an SQ-standardized grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy 61, 181-184 (2006).
19. Malling H.J., L. Lund, H. Ipsen, L. Poulsen: Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets. J. Invest. Allergol. Clin. Immunol. 16, 162-168 (2006).
20. Ring J.: Angewandte Allergologie. Urban und Vogel, 3. Auflage, München 2004.
21. Ring J., T. Fuchs, G. Schultze-Werninghaus: Weißbuch Allergie in Deutschland. Urban und Vogel, 2. Auflage, München 2004.
22. Ring J., U. Krämer, T. Schäfer, H. Behrendt: Why are allergies increasing? Curr. Opin. Immunol. 13, 701-708 (2001).
23. Wilson D.R., L.I. Torres, S.R. Durham: Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst. Rev. CD002893 (2003).
24. Winther L., J. Arnved, H.J. Malling, H. Nolte, H. Mosbech: Side-effects of allergen-specific immunotherapy. A prospective multicenter study. Clin. Exp. Allergy 36, 254-260 (2006).